Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients: A randomized controlled comparison with zidovudine monotherapy

JAMA

Volumn 276, Issue 2, 1996, Pages 111-117

  Staszewski, Schlomo ^a   Loveday, Clive ^b   Picazo, Juan J ^c   Dellamonica, Pierre ^d   Skinhøj, Peter ^e   Johnson, Margaret A ^f   Danner, Sven A ^g   Harrigan, P Richard ^h   Hill, Andrew M ⁱ   Verity, Lucy ⁱ   McDade, Hugh ⁱ  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^e University of Copenhagen   (Denmark)

^f ROYAL FREE HOSPITAL   (United Kingdom)

^g ACADEMIC MEDICAL CENTER   (Netherlands)

^h WELLCOME RESEARCH LABORATORIES   (United Kingdom)

ⁱ GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; PLACEBO; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MIXTURE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

EID: 8944245852     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.276.2.111     Document Type: Article

References (39)

1. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med. 1987;317:185-191.
2. Fischl MA, Richman DD, Hansen N, et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection: a double blind, placebo-controlled trial. Ann Intern Med. 1990;112:727-737.
3. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med. 1990;322:941-949.
4. Concorde Co-ordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom free HIV infection. Lancet. 1994;348:871-881.
5. Volberding PA, Lagakos SW, Grimes JM, et al. The duration of zidovudine benefit in persons with asymptomatic HIV infection. JAMA. 1994;272:437-442.
6. D'Aquila RT, Johnson VA, Welles SL, et al. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med. 1995; 122:401-408.
7. Kahn JD, Lagakos SW, Richman DD, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med. 1992;327:581-587.
8. Hammer S. Virologic markers and outcome in ACTG 175. In: Program and abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections; January 28-February 1, 1996; Washington, DC. Abstract S24.
9. Gazzard B, on behalf of the DELTA International Co-ordinating Committee. Further results of the European/Australian DELTA trial. In: Program and abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections; January 28-February 1, 1996; Washington, DC. Abstract LB5a.
10. Van Leeuwen R, Katlama C, Kitchen V, et al. The safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic HIV-1 infection: a phase I/II study. J Infect Dis. 1995;171:1168-1171.
11. Pluda JM, Cooley TP, Montaner JSG, et al. Phase I/II study of 2′-deoxy-3′-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection. J Infect Dis. 1995;171:1438-1447.
12. Viner KC, Cammack N, Coates JAV, et al. (-) Enantiomeric 2′-deoxy-3′-thiacytidine (3TC) in combination with AZT synergistically inhibits clinical isolates of HIV-1. In: Program and abstracts of the 9th International Conference on AIDS; June 6-11, 1993; Berlin, Germany. Abstract PO A25 0607.
13. Schuurman R, Nijhuis M, van Leeuwen R, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis. 1996;171:1411-1419.
14. Tisdale M, Kemp SD, Parry NR, et al. Rapid in vivo selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMMDD region of reverse transcriptase. Proc Natl Acad Sci U S A. 1993;90:5653-5656.
15. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral potency of AZT-3TC combination therapy. Science. 1995;269: 696-699.
16. Rana KZ, Horton CM, Yuen GJ, et al. Effect of lamivudine on zidovudine pharmacokinetics in asymptomatic HIV-infected individuals. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 4-7, 1994; Orlando, Fla Abstract A62:83.
17. Mulder J, McKinney N, Christopherson C, et al. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol. 1994;32:292-300.
18. Lin HJ, Myers LE, Yen-Lieberman B, et al. Multicenter evaluation of quantification methods for plasma human immunodeficiency virus type 1 RNA. J Infect Dis. 1994;170:553-562.
19. Van Gemen B, van Beuningen R, Nabbe A, et al. A one-tube quantitative HIV-1 RNA nucleic acid amplification assay (NASBA) using electrochemiluminescent (ECL) labelled probes. J Virol Methods. 1994;49:167-168.
20. Kaye S, Loveday C, Tedder R. A microtiter format point mutation assay: application to the detection of drug resistance in human immunodeficiency virus type-1 infected patients with zidovudine. J Med Virol. 1992;37:241-246.
21. Centers for Disease Control and Prevention. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep. 1992;41(RR-17):1-19.
22. National institute of Allergy and Infectious Diseases, Division of AIDS. Table for Grading Severity of Adult Adverse Experiences. Bethesda, Md: National Institute of Allergy and Infectious Diseases; August 1992.
23. Van Elteren PH. On the combination of independent two-sample tests of Wilcoxon. Bull Int Stat Inst. 1960;37:351-361.
24. 2 tests. Biometrics. 1954;10:417-451.
25. Dawson JD. Comparing treatment groups on the basis of slopes, areas under-the-curve, and other summary measures. Drug Info J. 1994;28:723-732.
26. Schooley RT, Ramirez-Ronda C, Lange J. Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. J Infect Dis. 1996;173:1364-1366.
27. Smaldone L. New drug application, for Zerit (Stavudine, d4T). Presented at the FDA Division of Antiviral Drug Products and Antiviral Drugs Advisory Committee; Novembers, 1995; Washington, DC.
28. Fischl MA, Stanley K, Collier AC, et al. Combination and monotherapy with zidovudine and zaicitabine in patients with advanced HIV disease. Ann Intern Med. 1995;122:24-32.
29. Meng TC, Fischl MA, Boota AM, et al. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection: a phase I/II study. Ann Intern Med. 1992;116:13-20.
30. Cooper DA, Gatell JM, Kroon S, et al. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. N Engl J Med. 1993;329:297-303.
31. Mellors JW, Kingsley LA, Rinaldo CR, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med. 1995; 122:573-679.
32. Loveday C, Hill A. Prediction of progression to AIDS with serum HIV-1 RNA and CD4 count. Lancet. 1995;346:790-791.
33. O'Brien WA, Hartigan PM, Martin D, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med. 1996;334:426-431.
34. Jackson B. Clinical Correlates of Viral and Immunologic Measurements in Zidovudine Naive or Experienced Subjects Who Received Zidovudine or Didanosine Therapy (ACTG 116A/116B/117).In: Program and abstracts of the 2nd National Conference on Human Retroviruses and Related Infections; January 29-Febroary 2,1995; Washington, DC.
35. Boyer PL, Hughes SH. Analysis of mutations at position 184 in reverse transcriptase of human immnunodeficiency virus type 1. Antimicrob Agents Chemother. 1995;39:1624-1628.
36. Wainberg MA, Gu Z. Targeting HIV reverse transcriptase in novel ways. Nat Med. 1995;1:628-629.
37. Wainberg MA, Drosopoulos WC, Salomon H, et al. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science. 1996;271:1282-1285.
38. Pandey VN, Kaushik N, Rege N, et al. Role of methionine 184 of human immunodeficiency virus type-1 reverse transcriptase in the polymerase function and fidelity of DNA synthesis. Biochemistry. 1996;35:2168-2179.
39. Eron JJ, Benoit SL, Jemsek J, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med. 1995;333:1662-1669.